TriSalus Life Sciences, Inc. — Director's Dealing 2023

Aug 15, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: TriSalus Life Sciences, Inc. (TLSI)
CIK: 0001826667
Period of Report: 2023-08-10

Reporting Person: Alecxih James (President, Device Technology)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	94754	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (right to buy)	$10.30	2033-05-18	Common Stock (94754)		Direct

Footnotes

F1: The securities reported herein were acquired by the Reporting Person prior to the Reporting Person becoming an executive officer of the Issuer. The Reporting Person was appointed as an executive officer of the Issuer effective immediately after the effective time of the Merger (as defined in that certain Agreement and Plan of Merger, dated as of November 11, 2022, as amended, by and among the Issuer, MTAC Merger Sub, Inc., and TriSalus Operating Life Sciences, Inc.).

F2: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 20, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

F3: Twenty-five percent of the shares subject to the option vest on February 20, 2024, the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.